Nitrendipine Viatris

Nitrendipine, the active ingredient in Nitrendipine Viatris, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by lowering blood pressure. GNH USA supplies Nitrendipine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nitrendipine is a dihydropyridine calcium‑channel blocker used in the management of arterial hypertension. - Hypertension: reduces peripheral vascular resistance and lowers systolic and diastolic blood pressure, helping to achieve target blood‑pressure goals.

Adverse reactions may occur with nitrendipine therapy.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warm sensation and redness, especially after the first doses. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, particularly when standing quickly. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Myocardial infarction: rare but possible in patients with pre‑existing coronary disease. - Cardiac arrhythmias: irregular heart rhythms requiring medical attention. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, pruritus, or anaphylaxis. - Angioedema: swelling of face, lips, or throat.

Before initiating nitrendipine, consider the following precautions. - Blood pressure monitoring: check baseline and regularly adjust therapy. - Concomitant antihypertensives: avoid excessive hypotension when combined with other agents. - Hepatic impairment: dose may need adjustment; monitor liver function. - Elderly patients: start at lower doses and monitor for dizziness. - CYP3A4 inhibitors: avoid strong inhibitors that can increase plasma levels. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nitrendipine may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise nitrendipine concentrations. - Other calcium‑channel blockers (e.g., amlodipine, felodipine): additive vasodilatory effect. - Grapefruit juice: can increase drug exposure and risk of hypotension. - Concurrent antihypertensives (e.g., ACE inhibitors, beta‑blockers): may cause excessive blood‑pressure fall.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance electrolyte shifts and orthostatic changes. - Beta‑blockers: may mask reflex tachycardia. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can attenuate antihypertensive response.